12:00 AM
 | 
Jun 06, 2005
 |  BioCentury  |  Product Development

Exelixis notches a deal

Research on the Notch pathway has been underway at small molecule developer Exelixis Inc. since the company was founded in 1994. But many of the ligands for Notch protein have unknown functions, which impedes approaches using small molecules. With last week's deal with Genentech Inc. to develop antibodies that target the pathway, EXEL thinks it can now move that asset forward at a reasonable pace....

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >